Hoofnagle JH, Sherker AH. Therapy for hepatitis C - the costs of success. N Engl J Med 2014;370:1552-3. [Ref.ID 97486]

Afdhal N, Reddy R, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian M, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, for the ION-2 investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93. [Ref.ID 97483]

Anónimo. Interférons alfa: décollements de rétine. Prescrire 2014;34:266. [Ref.ID 97437]

Editorial. Only just the begining of the end hof hepatiis C. Lancet 2014;383:281. [Ref.ID 97073]

Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [Ref.ID 96072]

Martínez Pascual C, Antón Ródenas G, Ortiz Sánchez ML, Pons Miñano JA. Hemofilia A adquirida secundaria al tratamiento con peginterferón alfa-2a en un paciente con hepatitis crónica por el virus C. Med Clin (Barc) 2013;141:228-9. [Ref.ID 96031]

Anónimo. Axitinib. Prescrire 2013;33:494-5. [Ref.ID 95937]

Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard P-M, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159:89-96. [Ref.ID 95863]

Anónimo. Neuropathies périphériques d'origine médicamenteuse. Prescrire 2013;33:269-75. [Ref.ID 95342]

van der Meer AJ, Hansen BE, Janssen HL. Sustained virological response to treatment in patients with chronic hepatitis C - Reply. JAMA 2013;309:1457. [Ref.ID 95266]

Maisonneuve P, Bruno S. Sustained virological response to treatment in patients with chronic hepatitis C. JAMA 2013;309:1457. [Ref.ID 95265]

Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013;75:931-43. [Ref.ID 95214]

Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a aystematic review. Ann Intern Med 2013;158:114-23. [Ref.ID 94775]

van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, Duarte-Rojo A, Heathcote J, Manns MP, Kuske L, Zeuzem S, Hofmann P, de Knegt RJ, Hansen BE, Janssen HL. Association betweeen sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93. [Ref.ID 94275]

Anónimo. FDA Drug Safety Communication: Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin. FDA 2012:1. [Ref.ID 93285]

Anónimo. Troubles de la vision des couleurs d'origine médicamenteuse. Prescrire 2012;32:113-6. [Ref.ID 92321]

Anónimo. Télaprévir. Hépatite C: après le bocéprévir, si besoin. Prescrire 2012;32:11-4. [Ref.ID 92252]

Anónimo. Bocéprévir. Avancée virologique dans l'hépatite C en trithérapie. Prescrire 2012;32:6-10. [Ref.ID 92251]

Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24. [Ref.ID 92234]

Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012;156:279-90. [Ref.ID 92167]